There is currently no evidence-based treatment for RP-ILD in anti-MDA5 antibody-positive patients; however, intensive immunosuppressive therapy initiated early in the disease, before irreversible lung damage, may improve patient survival [2]. The gene discussed is IFIH1; the disease is retinitis pigmentosa 1.